| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 18.6 | 5.2 |
| Profit before tax | -119.0 | -162.2 |
| Net income | -119.0 | -162.3 |
| EPS (diluted, $ a share) | $-0.22 | $-0.36 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +258.5% |
|---|
10-Q filed with the SEC, NASDAQ: RXRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Recursion Pharmaceuticals, Inc.: key numbers
- Share price
- $2.90Close, Nov 16
- Market cap
- $1.81B
- Shares outstanding
- 622.76MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Recursion Pharmaceuticals, Inc.
All →Recursion Pharmaceuticals Insider Blake Borgeson Sells $155K of Stock
Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals, Inc. at $3.88 a share, worth $155K in total on Nov 3, 2026. Shares held after the trade: 6,068,287 (-0.7%).
- Value
- $155K
- Shares
- 40,000
- Price
- $3.88
- Holding change
- -0.7%
- Trade date
- Nov 3, 2026
Recursion Pharmaceuticals Financial Results
Recursion Pharmaceuticals reported Q3 2026 financial results, highlighting clinical data for REC-4881 and REC-1245 and the appointment of Fred Hassan as Chair of the Board. The company extended its cash runway into 2029 following an October follow-on offering and noted that Sanofi has optioned the first development candidate from their collaboration.
- Term
- Q3 2026
“To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients.”
Najat Khan, Ph.D., President and Chief Executive Officer of Recursion
Recursion Pharmaceuticals Capital Raise of $200M
Recursion Pharmaceuticals entered into an underwriting agreement to raise approximately $200 million through a public offering of 61,540,000 shares of Class A common stock at $3.25 per share. The company also announced that Sanofi exercised an option for a first-in-class immunology development candidate under their existing collaboration, triggering a $10 million milestone payment. Proceeds from the equity raise are expected to extend the company's cash runway into 2029.
- Value
- $200M
- Counterparty
- Leerink Partners LLC
Recursion Pharmaceuticals Insider Blake Borgeson Sells $242K of Stock
Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals, Inc. at $4.84 a share, worth $242K in total on Oct 6, 2026. Shares held after the trade: 6,108,287 (-0.8%).
- Value
- $242K
- Shares
- 50,000
- Price
- $4.84
- Holding change
- -0.8%
- Trade date
- Oct 6, 2026
Recursion Pharmaceuticals Insider Robert Hershberg Sells $125K of Stock
Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals, Inc. at $5.00 a share, worth $125K in total on Oct 6, 2026. Shares held after the trade: 162,156 (-13.4%).
- Value
- $125K
- Shares
- 25,000
- Price
- $5.00
- Holding change
- -13.4%
- Trade date
- Oct 6, 2026
Recursion Pharmaceuticals Licensing Deal with Tempus AI, Inc. Worth $12M
Recursion Pharmaceuticals granted Tempus AI a non-exclusive license to its TxFM RNA sequencing model for use in oncology in exchange for a $12 million license fee. Simultaneously, the parties amended an existing master agreement to extend its term to six years and restructure annual license fees, while Recursion gained access to additional de-identified pathology records.
- Value
- $12M
- Counterparty
- Tempus AI, Inc.
- Term
- 2 years